167 related articles for article (PubMed ID: 27518544)
1. Licence to save: a UK survey of anti-VEGF use for the eye in 2015.
Shalaby AK; Lewis K; Bush K; Meredith PR; Di Simplicio S; Lockwood AJ
Eye (Lond); 2016 Nov; 30(11):1404-1406. PubMed ID: 27518544
[No Abstract] [Full Text] [Related]
2. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective.
van Asten F; Michels CTJ; Hoyng CB; van der Wilt GJ; Klevering BJ; Rovers MM; Grutters JPC
PLoS One; 2018; 13(5):e0197670. PubMed ID: 29772018
[TBL] [Abstract][Full Text] [Related]
3. Open Payments Database: Anti-Vascular Endothelial Growth Factor Agent Payments to Ophthalmologists.
Singh N; Chang JS; Rachitskaya AV
Am J Ophthalmol; 2017 Jan; 173():91-97. PubMed ID: 27697472
[TBL] [Abstract][Full Text] [Related]
4. Cost and Selection of Ophthalmic Anti-Vascular Endothelial Growth Factor Agents.
Li E; Greenberg PB; Voruganti I; Krzystolik MG
R I Med J (2013); 2016 May; 99(5):15-7. PubMed ID: 27128510
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model.
Vottonen P; Kankaanpää E
Acta Ophthalmol; 2016 Nov; 94(7):652-656. PubMed ID: 27481048
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.
O'Malley PG
Arch Intern Med; 2012 Jul; 172(13):1014-5. PubMed ID: 22688778
[No Abstract] [Full Text] [Related]
7. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
[TBL] [Abstract][Full Text] [Related]
8. Drugs for macular degeneration, price discrimination, and Medicare’s responsibility not to overpay.
Silver J
JAMA; 2014 Jul; 312(1):23-4. PubMed ID: 24860863
[No Abstract] [Full Text] [Related]
9. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network.
Jampol LM; Glassman AR; Bressler NM
JAMA Ophthalmol; 2015 Sep; 133(9):983-4. PubMed ID: 26087135
[No Abstract] [Full Text] [Related]
11. [Age-related visual loss].
Neubauer AS; Kernt M
MMW Fortschr Med; 2013 Feb; 155(2):36-7. PubMed ID: 23573743
[No Abstract] [Full Text] [Related]
12. Off-label prescribing in macular degeneration.
McCartney M
BMJ; 2011 Oct; 343():d6778. PubMed ID: 22012651
[No Abstract] [Full Text] [Related]
13. High Variation of Intravitreal Injection Rates and Medicare Anti-Vascular Endothelial Growth Factor Payments per Injection in the United States.
Erie JC; Barkmeier AJ; Hodge DO; Mahr MA
Ophthalmology; 2016 Jun; 123(6):1257-62. PubMed ID: 26976701
[TBL] [Abstract][Full Text] [Related]
14. Safety and complications of intravitreal injections performed in an Asian population in Singapore.
Xu Y; Tan CS
Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451
[TBL] [Abstract][Full Text] [Related]
15. A licence to cure.
Aronson JK; Ferner RE
BMJ; 2015 Apr; 350():h1723. PubMed ID: 25834026
[No Abstract] [Full Text] [Related]
16. Canadian preference and trends survey results for anti-VEGF treatment of macular edema.
Rayat JS; Grewal PS; Whelan J; Tennant MT; Choudhry N
Can J Ophthalmol; 2016 Jun; 51(3):233-7. PubMed ID: 27316276
[No Abstract] [Full Text] [Related]
17. The diabetic retinopathy clinical research network analysis of the cost-effectiveness of aflibercept, bevacizumab and ranibizumab for the treatment of diabetic macular oedema and its application in Spain.
Navarro-Navarro A; Salom D; Martínez-Toldos JJ; Udaondo P; Fernández-Martínez C; Gutiérrez-Arias L; Hervás A; Rodrigo R
Arch Soc Esp Oftalmol; 2017 May; 92(5):245-246. PubMed ID: 28215618
[No Abstract] [Full Text] [Related]
18. Higher priced drugs are not cost effective for diabetic macular edema, US study finds.
McCarthy M
BMJ; 2016 Jun; 353():i3253. PubMed ID: 27283845
[No Abstract] [Full Text] [Related]
19. Long-Term Effect of Anti-VEGF Agents on Intraocular Pressure in Age-Related Macular Degeneration.
Beato J; Pedrosa AC; Pinheiro-Costa J; Freitas-da-Costa P; Falcão MS; Melo A; Estrela-Silva S; Falcão-Reis F; Carneiro ÂM
Ophthalmic Res; 2016; 56(1):30-4. PubMed ID: 27046391
[TBL] [Abstract][Full Text] [Related]
20. [Anti-VEGF therapy for neovascular age-related macular degeneration -therapeutic strategies: statement of the German Ophthalmological Society, the German Retina Society and the Professional Association of Ophthalmologists in Germany - November 2014].
Deutsche Ophthalmologische Gesellschaft
Ophthalmologe; 2015 Mar; 112(3):237-45. PubMed ID: 25739373
[No Abstract] [Full Text] [Related]
[Next] [New Search]
